ProCE Banner Activity

Strategies for Optimal HIV Treatment and Prevention: Considering Bictegravir in Pregnancy

Multimedia

Should you continue or switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen? In this case example, learn about available data and recommendations for the use of bictegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen.

Released: September 28, 2022

Expiration: September 27, 2023

No longer available for credit.

Share

Faculty

William R. Short

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS: non-CME/CE services: Janssen; consultant: ViiV Healthcare.

Staff Disclosure

Staff

Jessica L. Adams, PharmD, AAHIVE

Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States

Jessica Adams, PharmD, BCPS, has no relevant financial relationships to disclose.

Ramya Moorthy,

Clinical Editor

Ramya Moorthy has no relevant financial relationships to disclose.

Ian Murphy, PhD

Ian Murphy, PhD, had no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.